Translation and Validation of Chinese COMPAT-SF
RecruitingNCT06917716
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this observational study is to translate, adapt, and test the reliability of a Chinese version of the Comprehensive Pain Assessment Tool Short Form (COMPAT-SF) for people with chronic pancreatitis. The study will answer these questions: * Does the Chinese COMPAT-SF work well to measure pain in people with chronic pancreatitis? * Is the Chinese COMPAT-SF accurate and reliable over time? Participants will: * Complete the Chinese COMPAT-SF questionnaire two times, with a 2-week gap. * Answer additional pain-related questions using the Brief Pain Inventory (BPI) and the Izbicki Pain Score. * Participate in a follow-up to check if the questionnaire gives consistent results over time. This study will help make sure that doctors in China have a useful and reliable tool to measure pain in people with chronic pancreatitis.
Study details
- Official title
- Translation and Validation of a Chinese Version of the Comprehensive Pain Assessment Tool Short Form (COMPAT-SF) in Patients With Chronic Pancreatitis
- Conditions
- Sponsor
- Changhai Hospital
- Start date
- 2025-03-10
- Primary completion
- 2026-06-30
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 1\. Diagnosed with chronic pancreatitis (CP) according to the Guidelines for the Diagnosis and Treatment of Chronic Pancreatitis in China (2018 edition). Diagnosis can be confirmed by: •Primary diagnostic criteria: (i) Definitive imaging findings, and (ii) Histopathological confirmation. •Secondary diagnostic criteria: (i) Recurrent upper abdominal pain, (ii) Abnormal serum amylase levels, (iii) Pancreatic exocrine insufficiency, (iv) Pancreatic endocrine insufficiency, (v) Pathogenic gene mutations, and (vi) History of heavy alcohol consumption. •Diagnosis is confirmed if at least one primary criterion or two secondary criteria are met. * 2\. Experience of pancreatic pain in the past 12 months Exclusion Criteria: * Under 18 years of age. * No pancreatic-related pain. * Diagnosed with pancreatic cancer or other tumors. * Presence of communication or reading impairments. * Refusal to participate in the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06917716